W. Wilmanns

7.0k total citations · 1 hit paper
265 papers, 5.0k citations indexed

About

W. Wilmanns is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, W. Wilmanns has authored 265 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Hematology, 66 papers in Molecular Biology and 57 papers in Oncology. Recurrent topics in W. Wilmanns's work include Hematopoietic Stem Cell Transplantation (27 papers), Acute Myeloid Leukemia Research (25 papers) and Testicular diseases and treatments (24 papers). W. Wilmanns is often cited by papers focused on Hematopoietic Stem Cell Transplantation (27 papers), Acute Myeloid Leukemia Research (25 papers) and Testicular diseases and treatments (24 papers). W. Wilmanns collaborates with scholars based in Germany, Switzerland and Israel. W. Wilmanns's co-authors include Ernst Holler, J. Mittermüller, Georg Ledderose, M. U. Heim, Ch. Clemm, G. Brehm, Rolf D. Issels, A. Gerl, C. Clemm and H. Sauer and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

W. Wilmanns

250 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1990 1.1k citations J. Mittermüller, Ernst Holler et al. Blood profile →

Peers

Countries citing papers authored by W. Wilmanns

Since Specialization

Citations

This map shows the geographic impact of W. Wilmanns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Wilmanns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Wilmanns more than expected).

Fields of papers citing papers by W. Wilmanns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Wilmanns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Wilmanns. The network helps show where W. Wilmanns may publish in the future.

Co-authorship network of co-authors of W. Wilmanns

This figure shows the co-authorship network connecting the top 25 collaborators of W. Wilmanns. A scholar is included among the top collaborators of W. Wilmanns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Wilmanns. W. Wilmanns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interstitielle Lupus-Nephritis 2008 ·DMW - Deutsche Medizinische Wochenschrift ·A. Gerl, W. Samtleben, (unknown), Reiner Bartl, (unknown), W. Wilmanns	0
2	Detection of Acute Myeloid Leukemic Cells in Complete Remission and in Extramedullary Sites by Clonal Analyses 1996 ·Acta Haematologica ·Helga Schmetzer, W. Wilmanns, H. Gerhartz	9
3	Testicular T umor afterCisplatin-Based Chemotherapyfor Germ Cell Malignancy 1994 ·European Urology ·A. Gerl, C. Clemm, Peter Köhl, W. Wilmanns	8
4	Prevention of graft‐versus‐host disease in DLA‐haplotype mismatched dogs and hemopoietic engraftment of CD6‐depleted marrow with and without cG‐CSF treatment after transplantation 1994 ·Tissue Antigens ·Michael Schumm, (unknown), Hans‐Jochem Kolb, P. Rieber, Matthias Büttner, (unknown), Elisabeth Kremmer, (unknown), (unknown), W. Wilmanns	11
5	NK activity of canine blood and marrow cells 1994 ·Tissue Antigens ·(unknown), Michael Schumm, Maike Buettner, (unknown), Elisabeth Kremmer, S. Thierfelder, W. Wilmanns, Hans‐Jochem Kolb	4
6	Testicular cancer and Hodgkin disease in the same patient 1993 ·Cancer ·A. Gerl, C. Clemm, Christoph Salat, J. Mittermüller, (unknown), W. Wilmanns	9
7	Effects of Tumor Necrosis-Factor on Primary Human Leukemia Cells: Ultrastructural Changes 1993 ·Acta Haematologica ·Reinhold Munker, (unknown), (unknown), Joachim W. Ellwart, R. Mailhammer, W. Wilmanns	9
8	Complement activation during storage of blood under normal blood bank conditions 1992 ·Blood ·Michael Schleuning, (unknown), (unknown), Marianne Jochum, M. U. Heim, W Mempel, W. Wilmanns	5
9	Paraneoplastic chronic intestinal pseudoobstruction as a rare complication of bronchial carcinoid. 1992 ·Gut ·A. Gerl, M. Storck, Andreas Schalhorn, Josef Müller‐Höcker, K.-W. Jauch, F. W. Schildberg, W. Wilmanns	40
10	Anti-TNF-alpha and Pentoxifylline for Prophylaxis of aGvHD in Murine Allogeneic Bone Marrow Transplantation 1992 ·Oncology Research and Treatment ·Ernst Holler, S. Thierfelder, Uta Behrends, (unknown), R. Hintermeíer-Knabe, H. Kolb, J. Kempeni, W. Wilmanns	5
11	Ergebnisse und therapeutische Konsequenzen der Staging Laparotomie beim Morbus Hodgkin 1991 ·Oncology Research and Treatment ·Erhard Hiller, H. Gerhartz, Markus Löffler, M. Pfreundschuh, (unknown), (unknown), Heiko Rühl, (unknown), W. Wilmanns, Volker Diehl	4
12	Low Incidence of Transplant-Related Complications in Patients with Chronic Release of Tumor Necrosis Factor-Alpha before Admission to Bone Marrow Transplantation: A Clinical Correlate of Cytokine Desensitization? 1991 ·Pathobiology ·Ernst Holler, R. Hintermeíer-Knabe, HJ Kolb, J. Kempeni, (unknown), S.M. Liesenfeld, (unknown), W. Wilmanns	7
13	Combination Chemotherapy with Vinblastine, Ifosfamide and Cisplatin in Bulky Seminoma 1989 ·Acta Oncologica ·C. Clemm, R. Hartenstein, N. Willich, Georg Ledderose, W. Wilmanns	12
14	Intensive Maintenance Treatment in Acute Myelogenous Leukemia (AML): Single Institution Experience of a Multicenter Randomized Trial 1988 ·Oncology Research and Treatment ·U. Jehn, (unknown), W. Wilmanns	5
15	Benefit and Costs of Follow-Up Programs in Nonseminomatous Germ Cell Tumors of the Stages Ilb–IV: The Munich Experience 1987 ·Oncology ·Wolfgang E. Berdel, C. Clemm, R. Hartenstein, (unknown), U. Fink, Johann Rastetter, W. Wilmanns	2
16	Untersuchungen über postmortal im Blut abgelaufene, koagulatorische und fibrinolytische Reaktionsmechanismen 1986 ·T Gilg, (unknown), (unknown), (unknown), G. Kauert, Wolfgang Eisenmenger, W. Wilmanns	2
17	Tumormarker in der Diagnostik von Aszites- und Pleurapunktaten 1986 ·Oncology Research and Treatment ·J. Mezger, R. Lamerz, H Arnholdt, D. Huhn, W. Wilmanns	5
18	Polychemotherapie fortgeschrittener Weichteilsarkome mit 4’-Epi-Doxorubicin (4’-Epi-DX) und Cisplatin (DDP) 1986 ·Oncology Research and Treatment ·(unknown), W Mair, U. Fink, (unknown), Ingvil Mjaaland, W. Wilmanns	2
19	INVITRO TREATMENT OF MARROW WITH ATCG OR CAMPATH-1 FOR PROPHYLAXIS OF GVHD - RESULTS OF THE AG-KMT MUNCHEN 1985 ·Experimental Hematology ·H. Kolb, H. Rodt, B. Netzel, G Hale, R. Haas, (unknown), W. Wilmanns, Herbert Waldmann, (unknown)	2
20	Metabolism of folio acid and of one-carbon units. 1963 ·Journal of Molecular Medicine ·L. Jaenicke, W. Wilmanns	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact